JP2023528561A5 - - Google Patents
Info
- Publication number
- JP2023528561A5 JP2023528561A5 JP2022560025A JP2022560025A JP2023528561A5 JP 2023528561 A5 JP2023528561 A5 JP 2023528561A5 JP 2022560025 A JP2022560025 A JP 2022560025A JP 2022560025 A JP2022560025 A JP 2022560025A JP 2023528561 A5 JP2023528561 A5 JP 2023528561A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- enhancement
- induction
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021013770 | 2020-03-29 | ||
| IN202021013770 | 2020-03-29 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021054151 | 2020-12-12 | ||
| IN202021054151 | 2020-12-12 | ||
| PCT/IN2021/050325 WO2021199078A2 (en) | 2020-03-29 | 2021-03-30 | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528561A JP2023528561A (ja) | 2023-07-05 |
| JP2023528561A5 true JP2023528561A5 (OSRAM) | 2024-08-16 |
Family
ID=77927896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560025A Pending JP2023528561A (ja) | 2020-03-29 | 2021-03-30 | 宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240226120A1 (OSRAM) |
| EP (1) | EP4126913A4 (OSRAM) |
| JP (1) | JP2023528561A (OSRAM) |
| CN (1) | CN115968375A (OSRAM) |
| AU (1) | AU2021247269A1 (OSRAM) |
| BR (1) | BR112022019649A2 (OSRAM) |
| IL (1) | IL296892A (OSRAM) |
| MX (1) | MX2022012165A (OSRAM) |
| WO (1) | WO2021199078A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
| CN115531315B (zh) * | 2022-12-05 | 2023-04-07 | 上海惠盾因泰生物科技有限公司 | 重组人干扰素λ1鼻喷雾剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080043A1 (en) * | 2002-03-18 | 2003-10-02 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
| EP1559423A1 (en) * | 2004-02-02 | 2005-08-03 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Medicinal acidic cannabinoids |
| US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| NL2009671C2 (en) * | 2012-10-19 | 2014-04-23 | Fytagoras B V | New antiviral use for acidic cannabinoids. |
| US10456435B2 (en) * | 2015-07-15 | 2019-10-29 | Christopher A. MCELVANY | Topical antiviral formulations and methods of using the same |
| WO2020257588A1 (en) * | 2019-06-20 | 2020-12-24 | Shaman Naturals, Llc | Compositions for preventing and treating viral infections |
| CN115916336A (zh) * | 2020-02-19 | 2023-04-04 | 施里玛·麦钱特 | 大麻二酚的组合物和治疗用途 |
| US11338010B2 (en) * | 2020-03-30 | 2022-05-24 | Suzhou Kintor Pharmaceuticals, Inc. | Systems, methods, and kits for diagnostics and treatment of viral respiratory infection |
| EP4149445A1 (en) * | 2020-05-11 | 2023-03-22 | ADD Advanced Drug Delivery Technologies, Ltd. | Uses and formulations of cannabinoids |
| WO2021231810A1 (en) * | 2020-05-14 | 2021-11-18 | Augusta University Research Institute, Inc. | Cannabidiol as a therapeutic modality for covid-19 |
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
-
2021
- 2021-03-30 IL IL296892A patent/IL296892A/en unknown
- 2021-03-30 JP JP2022560025A patent/JP2023528561A/ja active Pending
- 2021-03-30 CN CN202180038369.XA patent/CN115968375A/zh active Pending
- 2021-03-30 EP EP21781346.8A patent/EP4126913A4/en not_active Withdrawn
- 2021-03-30 US US17/915,862 patent/US20240226120A1/en not_active Abandoned
- 2021-03-30 AU AU2021247269A patent/AU2021247269A1/en active Pending
- 2021-03-30 WO PCT/IN2021/050325 patent/WO2021199078A2/en not_active Ceased
- 2021-03-30 MX MX2022012165A patent/MX2022012165A/es unknown
- 2021-03-30 BR BR112022019649A patent/BR112022019649A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dastan et al. | Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial | |
| Ye et al. | The pathogenesis and treatment of theCytokine Storm'in COVID-19 | |
| Goyal et al. | Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review | |
| WO2021023263A1 (zh) | 产生安全量的一氧化氮的药物组合物及其用途 | |
| JP2023537229A5 (OSRAM) | ||
| Khatri et al. | Nitazoxanide/Camostat combination for COVID-19: an unexplored potential therapy | |
| LT5079B (lt) | Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai | |
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| Kumar | Novel coronavirus (COVID-19) outbreak: Hope and search for effective therapeutic agent | |
| WO2012040164A2 (en) | Tlr5 ligands, therapeutic methods, and compositions related thereto | |
| Wang et al. | The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases | |
| Stebbing et al. | Kaposi's sarcoma—an update | |
| CN102772398A (zh) | 二氢杨梅素在制备防治流感药物中的应用 | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| RU2297846C2 (ru) | Способ лечения очагового и инфильтративного туберкулеза легких | |
| CN107149609B (zh) | 紫菜多糖在制备治疗手足口病毒感染的药物中的应用 | |
| Sowmya | Drugs used against COVID-19 | |
| JPWO2025105377A5 (OSRAM) | ||
| KR100805996B1 (ko) | 항-바이러스 의약 및 항암 의약을 제조하기 위한파라폭스바이러스 오비스 균주의 용도 | |
| Patrisio | Host-microbe-drug triad: Role of chloroquine/hydroxychloroquine in Covid-19 treatment-focus on inflammatory cytokine inhibition | |
| WO2024077509A1 (zh) | 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 | |
| Kovesdi et al. | Natural and artificial viral interference in viral diseases | |
| Ortiz et al. | New Drugs in Synthesis Research for Viral Diseases | |
| Yehia et al. | Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection |